Name | Cyclopropyl 2-fluorobenzyl ketone |
Synonyms | prasugrl I 150322-73-91 Cyclopropyl 2-fluorobenzylketone Cyclopropyl 2-fluorobenzyl ketone 2-fluorobenzyl cyclopropyl ketone 1-cyclopropyl-2-fluorobenzyl ketone 1-Cyclopropyl-2-(2-fluorophenyl)ethanone 1-cyclopropyl-2-(2-fluoro-phenyl)-ethanone 1-CYCLOPROPYL-2-(2-FLUORO-PHENYL)-ETHANONE Ethanone, 1-cyclopropyl-2-(2-fluorophenyl)- 1-cyclopropyl-2-(2-fluorophenyl)-Ethanone (prasugrel) Chemical intermediate for Prasugrel,Cyclopropyl 2-fluorobenzyl ketone |
CAS | 150322-73-9 |
EINECS | 1592732-453-0 |
InChI | InChI=1/C11H11FO/c12-10-4-2-1-3-9(10)7-11(13)8-5-6-8/h1-4,8H,5-7H2 |
InChIKey | DWBGTJUQWKWYGB-UHFFFAOYSA-N |
Molecular Formula | C11H11FO |
Molar Mass | 178.2 |
Density | 1.192±0.06 g/cm3(Predicted) |
Boling Point | 61°C/0.2mmHg(lit.) |
Flash Point | 107.942°C |
Solubility | Chloroform (Slightly), DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slig |
Vapor Presure | 0.018mmHg at 25°C |
Appearance | Oil |
Color | Colourless to Light Yellow |
Storage Condition | Sealed in dry,Room Temperature |
Refractive Index | 1.5150-1.5190 |
prasugrel intermediate | the developed thienopyridine antiplatelet agent is a prodrug that forms an active molecule after metabolism in the liver through cytochrome P450, it binds to platelet P2Y12 receptor and exerts anti-platelet aggregation activity. Clinical studies have shown that the 60 mg dose has a better anticoagulant effect than the standard dose of clopidogrel 300 mg and the increased dose of 600 mg, which can reduce the combined risk of heart attack, stroke and death due to heart disease by 20%, and quick, good curative effect, good drug resistance and bioavailability, low toxicity. Prasugrel also has stronger performance than clopidogrel in stable angina and acute coronary syndrome intervention, but the stronger the antiplatelet effect, the more likely it is to cause bleeding. The key question now is how do we clinically identify patients at high risk of thrombosis and how do we identify people at high risk of bleeding so that prasugrel and clopidogrel can be used differently in the two high risk groups, both reduce coronary thrombosis and avoid major bleeding. On December 18, 2008, prasugrel received its first important international recognition, and the European Committee for Medical Products (CHMP) of the European Medicines Agency recommended approval of the drug. Approval by the European Commission was passed in late February 2009. In Europe, it is sold under the trade name Efient for the treatment of acute coronary syndromes. Prasugrel works by inhibiting platelet activation and concurrent aggregation by blocking the P2Y12 adenosine diphosphate receptor on the platelet surface. Antiplatelet drugs are used to prevent platelets from aggregating or sticking together, which can lead to blockage of an artery and may trigger a heart attack or stroke. S. Food and Drug Administration approved prasugrel tablets for use in patients undergoing angioplasty to reduce the risk of blood clots. It was approved in Canada in April 2010 for the treatment of acute coronary syndrome. The label for prasugrel has a boxed warning sign that the drug can cause significant and sometimes fatal bleeding. This product should not be used in the following patients: current pathological bleeding; History of transient ischemic attack or stroke; Or emergency surgery, including coronary artery bypass surgery. |